Abstract. Epigallocatechin-3-gallate (EGCG), a major polyphenolic constituent of green tea, can exert growth suppressive effect on human pancreatic cancer cells by evoking apoptotic response. EGCG-induced apoptosis of pancreatic cancer cells is accompanied by growth arrest at an earlier phase of cell cycle along with depolarization of mitochondrial membrane. In this report, using MIA PaCa-2 cells as in vitro model, we demonstrate EGCG-induced cell death involves activation of caspase-8 and disappearance of intact 21 kDa Bid protein.
Introduction
The development of malignancies is a multi-step process that comprise of initiation, progression, invasion and finally establishment of metastasis. The multiple genetic alterations at each stage impart selective advantage over normal counterpart. In this respect, pancreatic carcinoma is no exception. During last decade, several cancer-causing genes have been found to be associated with pancreatic carcinoma (1) (2) (3) . Undoubtedly, the identification of these cancer-related genes have substantially improved our knowledge on pancreatic cancer development. However, the treatment of this cancer has not advanced that much. This might be due to the lack of early diagnosis and effective chemotherapeutic treatments. In pursuit to achieve a greater survival rate of pancreatic cancer patients, new molecular targets for drug discovery, better diagnosis markers as well as development of potential chemopreventive agents are absolutely necessary at this stage.
Cancer prevention by employing naturally occurring agents against defined molecular targets is a rational approach (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Catechins are the key components of tea that exert antiproliferative properties. Among them, the most abundant in tea extract, epigallocatechin-3-gallate (EGCG) was observed to effectively inhibit tumorigenesis and tumor growth in preclinical animal models (15, 16) . The bioavailability studies with this compound reveal the evidence of its wide distribution in mouse organs including pancreas. Ample animal studies exhibited the broad spectrum cancer preventive activities of tea constituents in different organs (5) . The mechanistic studies on the action of EGCG in different cancer cells indicate that multiple pathways might be involved to exert its anticancer activity. The ability of EGCG to inhibit MAP kinases and P13K/AKT pathway, NF-κB and AP-1 mediated transcription or growth factor mediated signaling was implicated with its cancer preventive action (5) . Moreover, several reports documented its inhibitory effect on angiogenesis as shown by suppression of endothelial cell growth and production of proangiogenic factor, VEGF (17, 18) .
Previously, we have observed that EGCG could invoke apoptosis in pancreatic carcinoma cells by Bax oligomerization, depolarization of mitochondrial membranes to facilitate cytochrome c release into cytosol (4). EGCG-induced stress signals also involved ROS mediated JNK activation in pancreatic cancer cells. The antiproliferative action of EGCG was associated with nuclear condensation, Poly-ADP ribose polymerase (PARP) cleavage as well as activation of executioner caspase-3.
Here we were interested to investigate the role of other caspases in EGCG mediated apoptosis. Our investigation indicates that EGCG mediated apoptosis of pancreatic carcinoma cells requires activation of both initiator and executioner caspases. In order to comprehend the mechanism of caspase-8 activation we employed RNase protection assay (RPA) using multi-probe template (6) set. It is evident that EGCG exposure induces the upregulation of death receptors in pancreatic cancer.
Since EGCG is able to trigger death receptor signaling, we examined the effects of EGCG and death receptor ligand TRAIL together in cell culture model. Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is a type II transmembrane cytokine and a potent inducer of apoptosis in cancer cells (6) . Interestingly, polyphenol EGCG can cooperate with TRAIL to enhance the sensitivity of pancreatic cancer cells to apoptosis in vitro.
Materials and methods
Cell culture. Human pancreatic cancer cell lines MIA PaCa-2 and Hs 766T were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). Cells were grown in RPMI supplemented with 10% FBS and 50 μg/ml gentamicin at 37˚C in a 5% CO 2 humidified atmosphere.
Apoptosis assay. Cells (5x10 6 ) were seeded (in triplicate plates) in the growth medium and the next day treated with EGCG (Sigma, MO) in the presence or absence of death receptor ligand TRAIL (R&D Systems, MN) for designated time periods. Dominant negative cDNA constructs encoding caspase-8, -9, FADD (6) in mammalian expression vectors were transiently transfected (6, 19, 20) prior to EGCG exposure. Subsequently, cells were either processed for chromatin condensation analysis by DNA group binding dye, 4', 6'-diamidino -2-phenylindole (DAPI) fluorescence or poly-ADP ribose polymerase (PARP) cleavage analysis (21) (22) (23) (24) (25) by immunoblotting with monoclonal antibody against PARP (BD Biosciences, CA). For DAPI staining, cells were washed and fixed followed by mounting in a fluid containing 2 μg/ml DAPI (Vector Laboratories, CA). A Nikon Eclipse E600 Fluorescence microscope was used to visualize nuclear stain.
Immunoblotting. MIA PaCa-2 cells at 5x10 6 /100 mm dish were seeded and treated 1 day later with specified concentrations of EGCG. For studies with death receptor ligands, cells were co-incubated with 5 ng/ml TRAIL (R&D Systems, MN) and 0.1 mM EGCG for designated time periods. Following treatment, total cellular proteins were extracted (6) (7) (8) (19) (20) (21) (22) (23) (24) (25) . After normalization for total protein content, the resulting lysate was subjected to SDS-PAGE and blotted into nitrocellulose membranes (Amersham Biosciences, NJ). Membranes were probed with the following antibodies: procaspase-8, -9 (Santa Cruz Biotechnology, CA), procaspase-3 (BD Biosciences), Bid (Cell Signaling, MA), Survivin (Novus Biologicals, CO), PARP (BD Biosciences). Immunodetection was accomplished by enhanced chemiluminescence method (Amersham). Immunoblotting with ·-tubulin or ß-actin antibodies (Sigma) was performed for protein loading control.
RNase protection assays. RNase protection assay (6) in control and EGCG treated pancreatic cancer cells was performed as described under the BD Riboquant multi-probe kit Instruction Manual (BD Biosciences). Total RNA (10 mg) isolated from each sample was hybridized with 8x10 5 cpm of labeled probe template set hAPO-3d in hybridization buffer. Hybridization reactions were initiated at 90˚C and allowed to cool down slowly to 56˚C. Subsequently, the samples were treated with RNaseA/RNaseT1 for 45 min at 30˚C followed by proteinase K digestion for 15 min at 37˚C. The samples were purified by phenol/chloroform extraction and ethanol precipitation. Finally the samples were resuspended in loading buffer (95% formamide; 0.025% xylene cyanol; 0.025% bromophenol blue; 0.5 mM EDTA and 0.025% SDS). The RNase-protected fragments were analyzed on a 5% denaturing polyacrylamide gel (19:1 acrylamide/bis) followed by autoradiography. The intensity of the signals was quantitated using a PhosphorImager system (Molecular Dynamics, Storm 860) and normalized using the housekeeping gene L32.
Clonogenic cell survival assay. MIA PaCa-2 cells were treated with EGCG alone, TRAIL alone or combination of EGCG and TRAIL for 24 h. Following treatment, cells were washed two times with phosphate buffered saline and then seeded in triplicate (10000 cells/10 cm dish). Cells were allowed to grow for additional two weeks in the absence of EGCG or TRAIL. Medium was changed every four days. Subsequently, cells were fixed with 4% buffered formalin and stained with 0.05% crystal violet for visualization and photography. The number of colonies was counted manually (26) .
Results

EGCG mediated apoptosis requires activation of caspase-8 and -9.
Our previous studies (4) revealed that EGCG is capable of promoting apoptosis in pancreatic cancer cells by inducing mitochondrial membrane depolarization, the downregulation of IAP family member, XIAP as well as caspase-3 activation. In order to further understand the molecular mechanism of EGCG action on apoptosis of pancreatic cancer cells, we were interested to examine the involvement of other caspases such as caspase-8 or -9. For this purpose, MIA PaCa-2 cells were treated with EGCG for 8-24-h time period and the activity was assessed by the disappearance of the inactive forms of procaspase-8 and -9 on Western blotting (Fig. 1) . The two species of procaspases observed here conform to previous reports (6) . As shown in Fig. 1A , MIA PaCa-2 cells exposed to EGCG for shorter period (8 h) did not undergo significant apoptosis (PARP cleavage). At the same time period, EGCG also cannot activate caspase-8 (Fig. 1A, lane 2) . However remarkable activation of caspase-8 was noted following 24-h treatment of EGCG. Similar kinetics of activation was observed for caspase-9 (Fig. 1B) .
Among the two major apoptotic pathways such as mitochondrial 'intrinsic' and transmembrane 'extrinsic', the latter one comprises of activation of death receptors (DR) such as Fas, TNF receptor 1, DR4 or DR5 (6, 27) . Apoptotic signal transduction cascade by extrinsic pathway ensues by the recruitment of DR associated molecules such as FADD to engage initiator caspase such as caspase-8. The activation of initiator caspases such as caspase-8 can cleave a proapoptotic protein Bid and translocation of truncated Bid (t-Bid) to mitochondria can orchestrate mitochondrial events that can result in biochemical as well as morphological alterations implicated with programmed cell death. In EGCG exposed pancreatic cancer cells, we also observed Bid cleavage (Fig. 1B) which is most likely executed by activated caspase-8. Moreover, EGCG treatment can down-regulate Survivin (Fig. 1C) , that is known to inhibit caspase activation therefore leading to negative regulation of apoptosis or programmed cell death.
To demonstrate whether FADD as well as caspase-8 are required for EGCG mediated death of pancreatic cancer cells, we determined the extent of apoptosis in cells transfected with pcDNA3 vector, DN-caspase-8 and DN-FADD respectively. In contrast to empty vector, all these dominant negative constructs inhibited EGCG-induced apoptosis (Fig. 1D) . We also investigated the effect of dominant negative construct of executioner caspase-9 on EGCG-induced cell death. The blocking of apoptosis by these DN constructs corroborates our biochemical data on activation of both caspase-8 and -9. Thus, EGCG-mediated demise of pancreatic cancer cells requires both caspase-8 and -9. (Fig. 1D ) prompted us to investigate the involvement of the death receptors in this process. In general, death receptors mediate apoptosis by recruiting FADD to the oligomerized death receptor complex where FADD facilitates the binding and activation of procaspase-8 or -10. Accordingly, we performed RNase protection assay (RPA) using multiprobe template set. The multiprobe RPA systems comprise of a series of templates with distinct length and sequence of selective mRNA species. Here we used specific probes for genes encoding death receptor (DR) family members (DR3, DR4, DR5, Fas, and FasL), caspase-8. Sequences from GAPDH and L32 mRNA were used as internal controls. Quantitation of death related genes revealed by RPA analysis demonstrates 1.5-2-fold increase in of DR4, DR5 and Fas mRNA ( Fig. 2A ) levels in EGCG exposed MIA PaCa-2 cells. On the contrary, mRNA levels of DRs remain unaltered in EGCG challenged Hs766T cells (Fig. 2C) . Of note, metastatic pancreatic cancer cells Hs766T are refractory to EGCGinduced apoptosis (4) . In order to corroborate our RPA data, cellular extract of EGCG-exposed MIA PaCa-2 cells was subjected to immunoblot analysis. Western blot analyses (Fig. 2B) clearly demonstrate increased levels of members (Fas, DR5) of death receptor family in MIA PaCa-2 cells when exposed for 24 h to EGCG.
Up-regulation of death receptors in EGCG sensitive pancreatic cancer cells. The significant inhibition of EGCG-induced cell death by transfection of dominant negative construct of FADD
Synergistic action of EGCG and TRAIL on pancreatic carcinoma cell death.
Our data indicating the ability of EGCG to up regulate death receptors in cultured pancreatic carcinoma cells led us to test whether EGCG in combination with death receptor ligand TRAIL can enhance the apoptosis inducing effect of EGCG. Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is a type II transmembrane cytokine and interacts with death receptors (DR4, DR5) to execute apoptosis in a variety of cancer cells (6, 27, 28) . As evident in Fig. 3A , TRAIL can further sensitize MIA PaCa-2 cells to EGCG-induced apoptosis (>2-fold). We next sought to affirm the synergy between EGCG and TRAIL by analysis of biochemical markers such as PARP cleavage or caspase-3 activation. The combination treatment of EGCG and TRAIL was very effective for enhanced PARP cleavage as well as for the disappearance of procaspase-3 (Fig. 3B) .
Combination treatment of EGCG and TRAIL diminishes survival of MIA PaCa-2 cells. As shown in Fig. 4 , the potential therapeutic synergy by combining EGCG and TRAIL was noted by significant apoptosis of pancreatic carcinoma cells. Next, we were interested to examine whether the combination therapy would exert any effect on colony growth. As evident from clonogenic survival assay (Fig. 4) , the number of colonies in EGCG or TRAIL treated MIAPaCa-2 cells was much higher than those formed by combination treatment (Fig. 4 , panel IV vs. panels II and III,). Our in vitro experiments Figure 2 . Effect of EGCG on death receptor related genes. A and C, Quantitation of death related genes revealed in RPA. MIA PaCa-2 (A) and Hs766T (C) cells were treated with or without EGCG for a period of 24 h. Total RNA was used in ribonuclease protection assay (RPA) using hAPO-3d probe (BD Biosciences). ImageQuant software was used to scan protected bands and counts were normalized against house keeping gene L32. Percent change in normalized count relative to control is presented. B, Induction of death receptor proteins Fas and DR5 following EGCG exposure. Immunoblot analysis of total cellular proteins isolated from EGCG exposed MIA PaCa-2 cells against Fas and DR5 antibodies. MIA PaCa-2 cells were exposed to either 50 μg/ml EGCG or 5 ng/ml of recombinant human TRAIL or 50 μg/ml EGCG and 5 ng/ml TRAIL together for 16 h. A, Cell death was determined by nuclear staining as described in Fig. 1 . The extent of apoptosis in EGCG exposed cells was considered to be 100%. B, Following designated treatment, cell free extract was subjected to Western blot analysis using monoclonal antibody against PARP and procaspase-3. Lane 1, control; lane 2, EGCG; lane 3, EGCG and TRAIL together; lane 4, TRAIL. demonstrate that the combination of EGCG and TRAIL resulted in enhanced growth inhibition compared with EGCG or TRAIL alone.
Discussion
Cancer of the pancreas stands out as a highly lethal disease with the poorest likelihood of survival among all of the major malignancies. Pancreatic cancer is often far advanced by the time symptoms occur and the diagnosis is established. As indicated by 8-year survival rates of <5%, the successful treatment of this cancer is rare. The development of malignancies is a multi-step process that comprise of initiation, progression and finally establishment of metastasis (1-3). The multiple genetic alterations at each stage impart selective advantage over normal counterpart and might contribute to resistance to therapy of this malignancy. Targeting apoptotic signaling machinery in pancreatic cancer might be a useful approach from therapeutic/prevention standpoint.
The data presented in this report indicate that polyphenolic constituent of green tea can render pancreatic cancer cells sensitive to death receptor ligand TRAIL mediated apoptosis possibly by upregulation of members of the death receptor family. At present the molecular mechanism of EGCGinduced upregulation of cell surface Fas/DR4/DR5 is not clear. However, as observed earlier (29, 30) one possibility might be AP-1 mediated transcriptional regulation of death receptors. Our previous report implicated a link between JNK pathway and EGCG mediated cell death (4). Activated JNK might lead to increase AP-1 expression (31, 32) . Interestingly, Fas promoter region has been shown to contain AP-1 binding site (29, 30) .
Further studies with dominant negative constructs of FADD, caspase-8 and -9 contribute to identify molecular components associated with EGCG mediated cell death of pancreatic carcinoma. The activation of death receptors signals the activation of caspase-8 leading to cleavage of proapoptotic protein Bid (Fig. 1) . The interaction of truncated Bid with Bax, either in the cytosol or on the mitochondrial surface, renders conformational changes in Bax. Proapoptotic Bax then inserts itself into outer mitochondrial membrane where it oligomerizes and facilitates release of cytochrome c from the intermembrane mitochondrial space. We have previously documented EGCG-induced Bax oligomerization and cytochrome c release from mitochondria to cytosol in MIA PaCa-2 cells (4). Here we have shown the disappearance of intact Bid in EGCG treated cells (Fig. 1B ). In addition, the level of Survivin, which is known to be the potent endogenous inhibitor of processed caspase-3, -7 and -9, is diminished following EGCG exposure (Fig. 1C) . Our cumulative studies demonstrate the convergence of mitochondrial machinery of apoptosis with death receptor pathway in EGCG mediated apoptosis of pancreatic cancer cells. Thus, cross-talk between extrinsic and intrinsic pathway might play a pivotal role in initiating apoptotic signaling cascade by EGCG.
Based on this, we employed combination treatment of EGCG and TRAIL that diminished survival of pancreatic cancer cells MIA PaCa-2. As shown in Fig. 3 , the potential therapeutic synergy by combining EGCG and TRAIL was noted by significant apoptosis of MIA PaCa-2 pancreatic carcinoma cells. In parallel, clonogenic survival assay demonstrated enhanced growth inhibition of MIA PaCa-2 cells when treated with EGCG and TRAIL together (Fig. 4) .
To the best of our knowledge, we report for the first time the efficacy of combination treatment of EGCG and TRAIL to sensitize demise of pancreatic cancer cells. In general, the constitutive activation of nuclear factor-kappaB is thought to contribute to develop TRAIL resistance in human pancreatic cancer cells (33) . Thus the ability of EGCG to augment sensitivity of TRAIL bears translational potential for therapy of TRAIL resistant pancreatic cancer. 
